Literature DB >> 26015871

Hemifacial spasm: 20-year surgical experience, lesson learned.

Hector Soriano-Baron1, Olivia Vales-Hidalgo2, Emiliano Arvizu-Saldana3, Sergio Moreno-Jimenez2, Rogelio Revuelta-Gutierrez2.   

Abstract

BACKGROUND: Hemifacial spasm is characterized by unilateral, paroxysmal, and involuntary contractions. It is more common in women on the left side. Its evolution is progressive, and it rarely improves without treatment.
METHODS: Microvascular decompressions (N = 226) were performed in 194 Hispanic patients (May 1992-May 2011). Outcomes were evaluated on a 4-point scale: Excellent (complete remission); good (1-2 spasms/day); bad (>2 spasms/day); and recurrence (relapse after initial excellent/good response).
RESULTS: Most patients were female (n = 123); 71 were male. Mean (±SD) age was 49.4 (±11.7) years; age at onset, 43.9 (±11.9) years; time to surgery, 5.7 (±4.7) years. The left side was affected in 114 patients. Typical syndrome occurred in 177 (91.2%); atypical in 17 (8.8%). Findings were primarily vascular compression (n = 185 patients): Anterior inferior cerebellar artery (n = 147), posterior inferior cerebellar artery (n = 12), basilar artery (n = 10), superior cerebellar artery (n = 8), and 2 vessels (n = 8); 9 had no compression. Postsurgical results were primarily excellent (79.9% [n = 155]; good, 4.6% [n = 9]; bad, 15.5% [n = 30]), with recurrence in 21 (10.8%) at mean 51-month (range, 1-133 months) follow-up. Complications included transient hearing loss and facial palsy.
CONCLUSIONS: The anterior inferior cerebellar artery is involved in most cases of hemifacial spasm. Failure to improve postsurgically after 1 week warrants reoperation. Sex, side, and onset are unrelated to treatment response. Microvascular decompression is the preferred treatment. It is minimally invasive, nondestructive, and achieves the best long-term results, with minor morbidity. To our knowledge, this series is the largest to date on a Hispanic population.

Entities:  

Keywords:  Cerebellopontine angle; facial nerve; facial tic; hemifacial spasm; microvascular decompression

Year:  2015        PMID: 26015871      PMCID: PMC4443403          DOI: 10.4103/2152-7806.157443

Source DB:  PubMed          Journal:  Surg Neurol Int        ISSN: 2152-7806


INTRODUCTION

Hemifacial spasm (HFS) is an overactive facial nerve dysfunction syndrome with spontaneous and gradual onset characterized by unilateral, clonic, paroxysmal, and involuntary contractions of one or more facial muscles innervated by the same facial nerve.[3611242526273361] In general, contractions occur spontaneously or are elicited by emotional stress, fatigue, or volitional movements of the face; contractions decrease during rest but may persist during sleep.[4261] HFS occurs almost exclusively in adults.[2834] It is not hereditary, although some familial cases have been described.[71436] HFS occurs slightly more often in women, typically on the left side. In rare cases, it is bilateral, but not symmetrical or synchronous.[2761] In general, HFS becomes worse over time.[31161] Untreated, it can be associated with mild ipsilateral facial paralysis[1133] or trigeminal neuralgia (i.e. tic convulsif [tic convulsive],[8] as first described by Cushing).[8946] The pathogenesis of HFS is not fully understood.[52] HFS is associated with compression of the facial nerve by a vascular loop at the entry point of the nerve root at the brainstem [Figure 1].[615243254] Some theories support a hyperexcitability of the facial motor nucleus in the brainstem[640] and psychosomatic factors.[46]
Figure 1

Vascular compression of the left facial nerve by the anterior inferior cerebellar artery (AICA) within the entry zone of the left facial nerve at the brainstem. CN indicates cranial nerve. Modified and used with permission from Zubay G, Porter RW, Spetzler RF: Transpetrosal approaches. Operative Techniques 4 (1):24-29, 2001

Vascular compression of the left facial nerve by the anterior inferior cerebellar artery (AICA) within the entry zone of the left facial nerve at the brainstem. CN indicates cranial nerve. Modified and used with permission from Zubay G, Porter RW, Spetzler RF: Transpetrosal approaches. Operative Techniques 4 (1):24-29, 2001 The diagnosis of HFS is clinical,[1837] although electrophysiology (electromyography) can be useful. Imaging studies, such as computed tomography, magnetic resonance imaging, and angiography, do not help establish the diagnosis but are useful in identifying associated pathology.[101743565758] Response is poor to medication therapy (e.g. carbamazepine, gabapentin).[15163953] Botulinum toxin type A is temporarily useful (transient improvement of 90–100%), but it requires repeat and frequent administration of injections; side effects include ptosis, keratitis, and diplopia.[3855] Currently, the best long-term control is achieved through microvascular decompression, first postulated by Gardner[15] and then popularized by Jannetta and colleagues.[82425262859] Continued improvement in surgical techniques has allowed surgeons to perform decompression with a minimally invasive approach.[38464759] The aim of this study was to analyze the demographics, clinical manifestations, outcomes, and complications of patients who underwent microvascular decompression of the facial nerve for the treatment of HFS at the National Institute of Neurology and Neurosurgery, Manuel Velasco Suárez, Mexico City, Mexico, between May 1, 1992, and May 31, 2011.[46]

MATERIALS AND METHODS

A total of 194 patients were diagnosed with HFS and surgically treated with microvascular decompression through a posterior fossa craniectomy by the senior author (R. R.-G.). A retrospective analysis was performed of the medical records of all patients to abstract sex, age, clinical history, evolution, previous treatment, preoperative imaging (computed tomography and/or magnetic resonance imaging), surgical findings, complications, outcomes, and response to treatment. Postsurgical follow-up was performed with postoperative clinic visits. This study was approved by the Institutional Review Board of the National Institute of Neurology and Neurosurgery. Postoperative results and follow-up findings were evaluated by the following criteria: (i) excellent: Complete remission of HFS (defined as 2 muscle spasms per week); (ii) good: 1 or 2 muscle spasms per day, with remarkable improvement from the preoperative state; (iii) bad: More than 2 muscle spasms per day, with slight improvement or status unchanged after surgery; and (iv) recurrence: Relapse of symptoms after initial excellent or good response. Statistical analysis (counts, percentages, mean [SD], Fisher's exact test, and the Chi-square test) was conducted using SPSS statistical software (IBM Corp). Significance was defined as P = 0.05.

RESULTS

A total of 226 microvascular decompressions were performed (194 first surgeries; 32 reinterventions) in 194 patients with HFS during the period of analysis.

Demographic findings

In this series of 194 patients, most were women (n = 123 [63.4%]); 71 were men (36.6%). The left side was affected in 114 patients (58.8%), the right side in 80 (41.2%). Patients ranged in age from 19 to 76 years (mean [±SD], 49.4 [±11.7] years). The mean (±SD [range]) age of onset was 43.9 years (±11.9 [range, 3–70] years), and the time to surgery was 5.7 years (±4.7 [1-30] years). There was only one case of bilateral HFS. This patient had an intervening span of 5 years before occurrence in the second side.

Clinical findings

By type of clinical onset, patients were classified into two groups: Typical syndrome and atypical syndrome. Typical HFS syndrome (onset in the upper hemiface, usually the lower eyelid, which progressed downward to affect the cheek and oral commissure) occurred in 177 patients (91.2%). Atypical syndrome (first affecting muscles of the mouth, then gradually spreading upward to the cheek and eyelid) occurred in 17 patients (8.8%). Two patients (1.0%) had tic convulsive. Prior to surgery, pharmacological therapy (e.g. carbamazepine, benzodiazepine) was used, with poor response, in 108 patients (55.7%). Nineteen patients previously treated with botulinum toxin type A injections had satisfactory temporary results lasting 4–6 months in most cases. One patient underwent microvascular decompression at another institution without postoperative clinical improvement. Preoperatively, all patients underwent audiological evaluation. Thirty-one patients had abnormal results on an auditory evoked potential test that suggested vascular compression; 28 patients were found to have ipsilateral nonuseful hearing; and the rest of the patients (n = 135) had a normal test. Four patients had tinnitus, 13 had facial hypoesthesia, and 13 had mild facial paralysis (House–Brackmann score < 3[19]). Preoperative imaging (computed tomography and/or magnetic resonance imaging) showed no anomalies in 112 patients. Fifty-two patients had a vascular loop compressing the facial nerve root at its entry point at the brainstem, and 30 patients had basilar artery ectasia.

Surgical findings

All 194 patients underwent surgery for vascular decompression of the entry point of the facial nerve root at the brainstem. An operative microscope and microsurgical instruments were used, with the patient in the park-bench position. The first 18 procedures were approached through a lateral suboccipital craniectomy, and the subsequent 176 were accessed via a retrosigmoid asterional craniectomy (maximum diameter, 20–25 mm). In two patients, endoscopy was used to facilitate the procedure. Vascular compression was identified in 185 patients. Nine patients showed no compression. In the 185 patients with vascular compression, the nerve root was isolated from the offending vessel by placing nonabsorbable material (Dacron [polyethylene terephthalate fiber] in 10 patients, Silastic [silicone rubber) in 15 patients, and Teflon [polytetrafluoroethylene] in 169 patients). Teflon was the preferred material because of its maneuverability and ease of use. In nine patients with no evidence of vascular compression, the surgeon performed compression of the facial nerve root to alleviate HFS. The most commonly identified offending vessel was the anterior inferior cerebellar artery (AICA) (n = 147 patients [75.8%]), followed by the posterior inferior cerebellar artery (PICA) (n = 12 [6.2%]), the basilar artery (n = 10 [5.2%]), and the superior cerebellar artery (n = 8 [4.1%]). More than one vessel (AICA and basilar artery) was involved in eight patients (4.1%), and no identifiable offending vessel was found in nine patients (4.6%).

Postoperative outcomes

After the first surgery, all conservative treatment was discontinued. The 4-point outcomes scale identified excellent results in 155 patients (79.9%), good results in 9 (4.6%), and bad results in 30 (15.5%). Of the 30 patients with bad results, 1 died after the first surgery. The remaining 29 patients underwent a reintervention using the same approach within a period of 2–7 days postoperatively. No additional vascular compression or other factors were evident that could explain the lack of response. Compression of the facial nerve root was therefore performed in all 29 patients, with excellent results in 26 patients and bad results in 3 patients who required a third surgery that resulted in excellent outcomes for all 3, for a total of 226 surgeries in 194 patients. During follow-up, 21 other patients (10.8%) had recurrence after initial surgery within 2 months to 3 years after surgery but declined additional surgeries.

Complications

Complications included paresis (House–Brackman score < 3) in 34 patients, with onset on postoperative day 1, with improvement during the first month of follow-up in 28 patients (mean, 4.5 days [range, 1–30 days]). Marked hearing loss developed in 29 patients, 10 of whom fully recovered postoperatively in the first month, and 19 of whom continued to have nonuseful hearing by audiometry at 6-month follow-up. Tinnitus was present in four patients, three of whom had complete resolution at 1-month follow-up. Other complications are summarized in Table 1.
Table 1

Complications After 226 microvascular decompressions in 194 patients with hemifacial spasm

Complications After 226 microvascular decompressions in 194 patients with hemifacial spasm

DISCUSSION

HFS is a relatively rare entity that occurs most commonly in middle-aged women. According to Auger and Whisnant,[4] HFS has an incidence of 0.8 cases per 100,000 persons, with a mean prevalence of 7.4 cases per 100,000 men and 14.5 per 100,000 women. Typical symptoms begin with intermittent contractions of the lower orbicular muscle, most commonly on the left side, which tend to extend ventrally to the rest of the ipsilateral facial muscles.[26] Although HFS is not painful, the associated stress it elicits interferes with activities of daily living, such as work, reading, and driving.[3659] The affected patients in our study were in the fifth and sixth decades of life, with a slight preponderance of women (63.4%) and with occurrence on the left side of the face (58.8%), consistent with results reported in the current medical literature.[152427] Some studies of Asian populations have shown a predominance in men and occurrence on the right side.[2054] Other signs or symptoms are not common; the incidence of associated facial paralysis has been reported in 10–57% of cases.[362061] However, we observed a lower incidence (6.7%) in our series. The pathogenesis of HFS, as described by Jannetta and colleagues,[6810152425262728404154] Moller,[40] and Shin et al.,[54] is believed to be secondary to neurovascular compression of the root of cranial nerve VII at its entry zone (at the transition between the central myelin and the peripheral myelin). This theory is widely accepted and recognized, but is also highly disputed. The diagnosis of HFS is clinical; electrophysiology and imaging studies are required to assess other pathologies of the cerebellopontine angle. In our study, no patients had associated tumors, aneurysms, arteriovenous malformations, arachnoid cysts, gliomas, brainstem strokes, or multiple sclerosis, which have been reported in previous studies of HFS.[1743565758] Differential diagnoses may include facial tic, postparalytic HFS, habitual spasm, facial myokymia, partial continuous epilepsy, essential blepharospasm, late dyskinesia, oromandibular dystonia, masticatory spasm, and Meige syndrome.[3551] Therapeutic options include medication, botulinum toxin type A injections, and surgical decompression. The most commonly used medications are carbamazepine, phenytoin, baclofen, and clonazepam.[151639415053] Subcutaneous injection of affected muscles with botulinum toxin type A produces complete or almost complete relief of symptoms in most (90–100%) patients. However, the improvement is only temporary (mean duration, 3–6 months), and periodic repeat dosing is required. In addition, botulinum toxin type A has been associated with multiple side effects, such as ptosis, keratitis, and diplopia.[3855] Microvascular decompression produces decreased interstitial resistance and allows myelin regrowth on affected fibers.[4551] The immediate relief of spasms can result from disappearance of the spontaneous or ectopic excitation caused by pulsating compression of the offending vessel.[404150] This improvement can result from the complete microstructural regeneration of the nerve[330] or from the gradual stabilization of the facial motor nucleus.[4050] In our series, the most commonly offending vessel was the AICA (75.8%). Other affected vessels were the PICA (6.2%), the basilar artery (5.2%), and the superior cerebellar artery (4.1%). Similar findings have been reported by Wilson et al.[60] (AICA 54.4%), Fairholm et al.[13] (AICA 66.6%), and Samii et al.[51] (AICA 54.5%), contrary to the findings of Barker et al.[635] and Loeser and Chen,[635] who found more cases of PICA. Reports of complete cessation of spasms document success rates of more than 50%, from lows of 60% (Loeser and Chen[35]), 63% (Kaye and Adams[29]), 64% (Neagoy and Dohn[44]), and 67% (Rushworth and Smith[49]), to highs of 78% (Fabinyi and Adams[12]), 80% (Rhoton[48]), 82% (Wilson et al.[60]), 88% (Auger[2]), and 93% (Jho and Jannetta).[28] We observed excellent results in 79.9%, good results in 4.6%, bad results in 15.5%, and recurrence in 10.8%. Sex, side, and onset were not statistically correlated with outcome [Table 2]. The reasons for recurrence and clinical failure after surgery are debatable.[55459] In some cases, an additional vessel can be identified; in others, there may be preoperative neuronal damage, perineural scar formation and/or arachnoid adhesions, indirect compression by the material used for decompression, or indirect compression by cerebrospinal fluid.[31] Current reports document a variable failure rate after a first surgery that ranges from lows of less than 15% (11.9% [Illingworth et al.[21]], 13.0% [Huang et al.[20], 13.0% [Kim and Fukushima[30]], and 13.6% [Iwakuma et al.[23]]) to highs of 22.7% (Augur[3]), 36.4% (Shin et al.[54]), and 50.3% (Ishikawa et al.[22]). In our series of 194 patients, 30 patients (15.5%) had bad results (including 1 death) after the first surgery, which is comparable with outcomes of other studies.[62032464761] Twenty-nine patients then underwent a second surgery, and 26 had excellent results, similar to outcomes of Barker et al.[6]
Table 2

Complete and partial cessation of hemifacial spasms in 194 patients by sex, side, and onset

Complete and partial cessation of hemifacial spasms in 194 patients by sex, side, and onset Ishikawa and colleagues[22] reported that patients with recurrent symptoms in the first 4 days after surgery require immediate exploration, and those with later recurrence without facial paresis are likely to improve within the next 8 months to 2 years. Twenty-one of our 194 patients had recurrence; none of them were taken to reexploration either because the patients did not approve an additional surgery or because they were still under surveillance (2 years after surgery) at the time of this review. In our study, the rate of permanent deficits was similar to those reported by Barker et al.,[6] Shin et al.,[54] and Loeser and Chen.[35] The most common complications were transient facial paresis and permanent hearing deficit, especially after reintervention, and these can be explained by the increased neural tissue manipulation or the presence of scar tissue.

CONCLUSIONS

Limitations of this study include those inherent to its retrospective nature and its inclusion of only a Hispanic population. Nonetheless, to our knowledge, this is the largest series to date on HFS in a Hispanic population. Previous reports have not analyzed the unique features of HFS in this population, which makes this study relevant to address the lack of knowledge in the field. Additional studies are needed to fully understand the nature of HFS, the response of patients to different treatment options, and the development of recurrence. So far, microvascular decompression offers the best long-term outcome for treatment of HFS, with low morbidity and mortality. Ongoing improvements in surgical techniques allow microvascular decompression to be performed through a minimally invasive approach. The most commonly implicated vessel is the AICA. Postoperative complications may be related to the experience of the surgeon, the necessity for reoperation, and the use of a refined surgical technique. Factors related to nonresponse or recurrence remain unknown. However, if surgery does not relieve the spasm during the first week, we recommend immediate reexploration.
  60 in total

Review 1.  Outcome after microvascular decompression for typical trigeminal neuralgia, hemifacial spasm, tinnitus, disabling positional vertigo, and glossopharyngeal neuralgia (honored guest lecture).

Authors:  P J Jannetta
Journal:  Clin Neurosurg       Date:  1997

Review 2.  Electrophysiology of the facial nerve in hemifacial spasm: ectopic/ephaptic excitation.

Authors:  V K Nielsen
Journal:  Muscle Nerve       Date:  1985-09       Impact factor: 3.217

3.  A hereditary neurological disease with facial spasm.

Authors:  P O Lundberg; C E Westerberg
Journal:  J Neurol Sci       Date:  1969 Jan-Feb       Impact factor: 3.181

4.  Microvascular decompression in hemifacial spasm: intraoperative electrophysiological observations.

Authors:  A R Møller; P J Jannetta
Journal:  Neurosurgery       Date:  1985-05       Impact factor: 4.654

5.  Hemifacial spasm. Comparison of three different operative procedures in 110 patients.

Authors:  T Iwakuma; A Matsumoto; N Nakamura
Journal:  J Neurosurg       Date:  1982-12       Impact factor: 5.115

6.  Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984.

Authors:  R G Auger; J P Whisnant
Journal:  Arch Neurol       Date:  1990-11

7.  Microvascular decompression of the facial nerve for hemifacial spasm: clinical and electrophysiologic observations.

Authors:  R G Auger; D G Piepgras; E R Laws; R H Miller
Journal:  Neurology       Date:  1981-03       Impact factor: 9.910

8.  Baclofen in hemifacial spasm.

Authors:  R Sandyk; M A Gillman
Journal:  Int J Neurosci       Date:  1987-04       Impact factor: 2.292

Review 9.  Hemifacial spasm: a prospective long-term follow up of 83 cases treated by microvascular decompression at two neurosurgical centres in the United Kingdom.

Authors:  R D Illingworth; D G Porter; J Jakubowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

10.  Microvascular decompression for hemifacial spasm.

Authors:  F G Barker; P J Jannetta; D J Bissonette; P T Shields; M V Larkins; H D Jho
Journal:  J Neurosurg       Date:  1995-02       Impact factor: 5.115

View more
  4 in total

1.  Fatal complications following microvascular decompression: could it be avoided and salvaged?

Authors:  Lei Xia; Ming-Xing Liu; Jun Zhong; Ning-Ning Dou; Bin Li; Hui Sun; Shi-Ting Li
Journal:  Neurosurg Rev       Date:  2016-10-12       Impact factor: 3.042

2.  Anatomical deviations of vertebral artery in hemifacial spasm: a quantitative study.

Authors:  Xianxia Yan; Junxiang Gu; Junjie Quan; Xi Zhang; Xiaoqian Zhou; Jianqiang Qu; Le Zhou
Journal:  Surg Radiol Anat       Date:  2020-11-01       Impact factor: 1.246

3.  Spasm Freedom Following Microvascular Decompression for Hemifacial Spasm: Systematic Review and Meta-Analysis.

Authors:  Katherine Holste; Ronald Sahyouni; Zoe Teton; Alvin Y Chan; Dario J Englot; John D Rolston
Journal:  World Neurosurg       Date:  2020-04-16       Impact factor: 2.104

Review 4.  Hearing Loss following Posterior Fossa Microvascular Decompression: A Systematic Review.

Authors:  Matthew Bartindale; Matthew Kircher; William Adams; Neelam Balasubramanian; Jeffrey Liles; Jason Bell; John Leonetti
Journal:  Otolaryngol Head Neck Surg       Date:  2017-09-12       Impact factor: 3.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.